For some added perspective on the second-quarter spike in biotech IPOs, we’re offering you Renaissance Capital’s updated snapshot on the last 7 years. Remember the bad old days back in 2011 and 2012, when only the very few — and very desperate — were able to make it back onto the market? The IPO hunger was satisfied with a big spike in Q1 2014, but the first half of this year has beat all the other previous H1 scores. It’s unlikely that Q3 or Q4 could measure up to the first three months of 2014 — and the current bullishness around biotech stocks could flag — but you’ll likely see plenty more lining up to give it a shot.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 37,600+ biopharma pros who read Endpoints News by email every day.Free Subscription